세계의 전이성 전립선암 시장 보고서(2025년)

Metastatic Prostate Cancer Global Market Report 2025

US $ 4,490 ￦ 6,516,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,490 ￦ 9,419,000

PDF (Site License)

PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,490 ￦ 12,322,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

전이성 전립선암 시장 규모는 향후 몇 년 동안 강력한 성장이 예상됩니다. 2029년에는 연평균 성장률(CAGR) 8.4%로 121억 6,000만 달러에 달할 전망입니다. 예측 기간 동안의 성장은 스크리닝 이니셔티브의 확대, 유리한 상환 정책, 첨단 치료법의 채택 확대, 신흥국 시장 확대 등의 요인에 기인하는 것으로 보입니다. 예측 기간의 주요 동향으로는 영상 진단 기술의 발전, 표적 치료의 혁신, 액체 생검의 개발, 면역 요법 연구개발의 진행, 최소 침습 수술 기술의 채택 등을 들 수 있습니다.

맞춤형 치료에 대한 수요 증가는 전이성 전립선암 시장의 성장을 견인할 것으로 예측됩니다. 개인 맞춤형 치료는 개인의 유전적 프로파일, 생활습관, 질환의 특성에 따라 맞춤화된 의료적 접근으로, 보다 목표에 맞는 효과적인 결과를 얻을 수 있는 의료적 접근법입니다. 이러한 수요는 유전체 프로파일링과 바이오마커 검사의 발전으로 특정 돌연변이 및 생물학적 마커를 식별하는 데 도움이 되는 유전체 프로파일링 및 바이오마커 검사의 발전으로 임상의가 환자별로 효과적일 가능성이 높은 치료법을 선택할 수 있게 됨에 따라 더욱 증가하고 있습니다. 바이오마커 유도 치료, 유전자 표적 치료와 같은 개인 맞춤형 치료 전략은 각 환자의 특정 종양 프로파일에 맞는 치료법을 적용하고, 부작용을 최소화하면서 효능을 향상시킴으로써 전이성 전립선암 관리에 혁명을 일으키고 있습니다. 예를 들어, Personalized Medicine Coalition의 보고서에 따르면, 미국 식품의약국(FDA)은 2023년 희귀질환에 대한 16개의 새로운 개인맞춤형 치료제를 승인했는데, 이는 2022년 6건에서 증가한 수치입니다. 이러한 개별화 접근법에 대한 수요 증가는 전이성 전립선암 시장의 성장에 박차를 가하고 있습니다.

전이성 전립선암 시장의 주요 기업들은 치료의 특이성을 높이고, 건강한 조직 손상을 줄이고, 환자의 예후를 개선하기 위해 표적 방사성 리간드 치료와 같은 첨단 치료법 개발에 집중하고 있습니다. 표적 방사성동위원소 치료는 특정 암세포를 표적으로 하도록 설계된 분자(리간드)와 해당 세포를 파괴하기 위해 국소적으로 방사선을 조사하는 방사성동위원소를 결합한 정밀 암 치료법입니다. 예를 들어, 2022년 3월 스위스 제약회사 NovartisAG는 전립선 특이적 막 항원(PSMA) 양성 전이성 거세 저항성 전립선암에 대한 최초의 표적 방사성 리간드 치료제인 플루빅토(Pluvicto)의 FDA 승인을 획득했습니다. 이 치료법은 전립선암 세포에 많이 존재하는 PSMA를 표적으로 하는 리간드에 방사성 동위원소인 루테튬177을 결합시켜 정확한 방사선 조사가 가능한 치료법입니다. 플루빅토는 전립선암 치료의 획기적인 치료제로, 다른 치료법을 다 써버린 환자의 무진행 생존기간을 크게 연장시킵니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세, 코로나재난과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계 성장 분석과 전략 분석 프레임워크

• 세계의 전이성 전립선암 : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
• 최종 이용 산업 분석
• 세계의 전이성 전립선암 시장 : 성장률 분석
• 세계의 전이성 전립선암 시장 실적 : 규모와 성장, 2019-2024년
• 세계의 전이성 전립선암 시장 예측 : 규모와 성장, 2024-2029년, 2034년
• 세계의 전이성 전립선암 : 전체 시장(TAM)

제6장 시장 세분화

• 세계의 전이성 전립선암 시장 : 치료 유형별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
• 화학요법
• 면역치료
• 호르몬 요법
• 방사선 치료
• 기타
• 세계의 전이성 전립선암 시장 : 투여 경로별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
• 경구
• 비경구 경로
• 정맥내
• 척수내
• 복강내
• 동맥내
• 국소
• 세계의 전이성 전립선암 시장 : 유통 채널별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
• 병원 약국
• 소매 약국
• 온라인 약국
• 기타
• 세계의 전이성 전립선암 시장 : 최종사용자별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
• 병원
• 클리닉
• 암센터
• 실험실
• 기타
• 세계의 전이성 전립선암 시장 : 화학요법별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
• Docetaxel
• Cabazitaxel
• Mitoxantrone
• 병용 화학요법
• 세계의 전이성 전립선암 시장 : 면역치료별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
• Sipuleucel-T
• 면역 관문 억제제
• 암백신
• 사이토카인 요법
• 세계의 전이성 전립선암 시장 : 호르몬 요법별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
• 황체 형성 호르몬 방출 호르몬(LHRH) 작용제
• LHRH 길항제
• 항안드로겐
• 안드로겐 합성 억제제
• 복합 안드로겐 차단(CAB)
• 세계의 전이성 전립선암 시장 : 방사선 요법별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
• 외부 방사선 치료(EBRT)
• 정위 방사선 치료(SBRT)
• 방사성 의약품 요법
• 강도조절 방사선 치료(IMRT)
• 세계의 전이성 전립선암 시장 : 기타별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
• 표적치료
• 골 표적치료
• 임상시험 약물
• 완화치료

제7장 지역별/국가별 분석

• 세계의 전이성 전립선암 시장 : 지역별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
• 세계의 전이성 전립선암 시장 : 국가별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 개요

• 전이성 전립선암 시장 : 경쟁 구도
• 전이성 전립선암 시장 : 기업 개요
  • Pfizer Inc.
  • Merck & Co. Inc.
  • AbbVie Inc.
  • Bayer AG
  • Bristol-Myers Squibb Company

제31장 기타 주요 기업 및 혁신 기업

• AstraZeneca PLC
• Novartis AG
• Astellas Pharma Inc.
• Ipsen Group
• Exelixis Inc.
• Ferring Pharmaceuticals
• Dendreon Pharmaceuticals LLC
• Hinova Pharmaceuticals Inc.
• Janux Therapeutics Inc.
• Zenith Epigenetics Ltd.
• Tavanta Therapeutics Inc.
• Cardiff Oncology Inc.
• Oncternal Therapeutics Inc.
• Clarity Pharmaceuticals Ltd.
• Convergent Therapeutics Inc.

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장 잠재력이 높은 국가, 전략

• 전이성 전립선암 시장, 2029년 : 새로운 기회를 제공하는 국가
• 전이성 전립선암 시장, 2029년 : 새로운 기회를 제공하는 부문
• 전이성 전립선암 시장, 2029년 : 성장 전략
  • 시장 동향에 의한 전략
  • 경쟁 전략

제36장 부록

LSH

영문 목차

영문목차

Metastatic prostate cancer is a severe stage of prostate cancer where cancer cells have spread from the prostate gland to other areas of the body, including bones, lymph nodes, or distant organs. This stage marks the progression of the disease beyond the prostate, helping guide treatment decisions aimed at slowing the spread, relieving symptoms, and improving survival outcomes.

The primary treatment options for metastatic prostate cancer include chemotherapy, immunotherapy, hormonal therapy, radiation therapy, and other methods. Chemotherapy employs potent drugs to target and destroy fast-growing cells, including cancer cells. It can be administered through various routes, such as oral, parenteral, intravenous, intrathecal, intraperitoneal, intra-arterial, and topical. These treatments are distributed through channels like hospital pharmacies, retail pharmacies, and online platforms, and are used by end users including hospitals, clinics, cancer centers, and research laboratories.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.

The metastatic prostate cancer market research report is one of a series of new reports from The Business Research Company that provides metastatic prostate cancer market statistics, including metastatic prostate cancer industry global market size, regional shares, competitors with a metastatic prostate cancer market share, detailed metastatic prostate cancer market segments, market trends and opportunities, and any further data you may need to thrive in the metastatic prostate cancer industry. This metastatic prostate cancer market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The metastatic prostate cancer market size has grown strongly in recent years. It will grow from $8.11 billion in 2024 to $8.81 billion in 2025 at a compound annual growth rate (CAGR) of 8.7%. The growth during the historic period can be attributed to several factors, including a growing aging population, a rising incidence of prostate cancer, increased awareness and screening programs, advancements in diagnostic techniques, and higher healthcare expenditure.

The metastatic prostate cancer market size is expected to see strong growth in the next few years. It will grow to $12.16 billion in 2029 at a compound annual growth rate (CAGR) of 8.4%. The growth during the forecast period can be attributed to factors such as expanding screening initiatives, favorable reimbursement policies, increased adoption of advanced therapies, and market expansion in emerging economies. Key trends in the forecast period include advancements in diagnostic imaging technology, innovations in targeted therapies, developments in liquid biopsy, ongoing research and development in immunotherapy, and the adoption of minimally invasive surgical techniques.

The increasing demand for personalized treatments is expected to drive the growth of the metastatic prostate cancer market. Personalized treatments are medical approaches that are customized based on an individual's genetic profile, lifestyle, and disease characteristics to achieve more targeted and effective results. This demand is growing due to advancements in genomic profiling and biomarker testing, which help identify specific mutations and biological markers, allowing clinicians to choose therapies that are more likely to be effective for each patient. Personalized treatment strategies, such as biomarker-guided therapies and gene-targeted drugs, are revolutionizing the management of metastatic prostate cancer by matching therapies to each patient's specific tumor profile, improving effectiveness while minimizing side effects. For instance, the Personalized Medicine Coalition reported that in 2023, the US Food and Drug Administration (FDA) approved 16 new personalized treatments for rare diseases, up from just 6 in 2022. This rising demand for personalized approaches is fueling the growth of the metastatic prostate cancer market.

Key players in the metastatic prostate cancer market are focusing on developing advanced treatments like targeted radioligand therapy to improve treatment specificity, reduce damage to healthy tissues, and enhance patient outcomes. Targeted radioligand therapy is a precision cancer treatment that combines a molecule (ligand) designed to target specific cancer cells with a radioactive isotope that delivers localized radiation to destroy those cells. For example, in March 2022, Novartis AG, a Swiss pharmaceutical company, received FDA approval for Pluvicto, the first targeted radioligand therapy for prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer. This therapy uses lutetium-177, a radioactive isotope, linked to a ligand targeting PSMA, a protein found in high levels on prostate cancer cells, enabling precise radiation delivery. Pluvicto represents a breakthrough in prostate cancer treatment, significantly extending progression-free survival in patients who have run out of other treatment options.

In June 2024, AstraZeneca PLC, a UK-based biopharmaceutical company, acquired Fusion Pharmaceuticals for $2.4 billion. With this acquisition, AstraZeneca aims to strengthen its next-generation radioconjugate platform and accelerate the development of targeted cancer therapies, particularly for metastatic castration-resistant prostate cancer and other solid tumors. Fusion Pharmaceuticals is a Canadian clinical-stage company focused on targeted therapies, including a potential treatment for metastatic castration-resistant prostate cancer (mCRPC).

Major players in the metastatic prostate cancer market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Bayer AG, Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, Astellas Pharma Inc., Ipsen Group, Exelixis Inc., Ferring Pharmaceuticals, Dendreon Pharmaceuticals LLC, Hinova Pharmaceuticals Inc., Janux Therapeutics Inc., Zenith Epigenetics Ltd., Tavanta Therapeutics Inc., Cardiff Oncology Inc., Oncternal Therapeutics Inc., Clarity Pharmaceuticals Ltd., and Convergent Therapeutics Inc.

North America was the largest region in the metastatic prostate cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in metastatic prostate cancer report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the metastatic prostate cancer market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The metastatic prostate cancer market consists of sales of radiopharmaceuticals, biosimilars, cancer pain management drugs, diagnostic imaging agents, and supportive care medications. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Metastatic Prostate Cancer Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on metastatic prostate cancer market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for metastatic prostate cancer ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The metastatic prostate cancer market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Treatment Type: Chemotherapy; Immunotherapy; Hormonal Therapy; Radiation Therapy; Other Treatments
• 2) By Route of Administration: Oral; Parenteral Route; Intravenous; Intrathecal; Intraperitoneal; Intra-Arterial; Topical
• 3) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy; Other Distribution Channels
• 4) By End User: Hospitals; Clinics; Cancer Centers; Research Laboratories; Other End-Users
• Subsegments:
• 1) By Chemotherapy: Docetaxel; Cabazitaxel; Mitoxantrone; Combination Chemotherapy Regimens
• 2) By Immunotherapy: Sipuleucel-T; Immune Checkpoint Inhibitors; Cancer Vaccines; Cytokine Therapies
• 3) By Hormonal Therapy: Luteinizing Hormone-Releasing Hormone (LHRH) Agonists; LHRH Antagonists; Anti-Androgens; Androgen Synthesis Inhibitors; Combined Androgen Blockade (CAB)
• 4) By Radiation Therapy: External Beam Radiation Therapy (EBRT); Stereotactic Body Radiotherapy (SBRT); Radiopharmaceutical Therapy; Intensity-Modulated Radiation Therapy (IMRT)
• 5) By Other Treatments: Targeted Therapy; Bone-Targeted Therapy; Clinical Trial Drugs; Palliative Therapy
• Companies Mentioned: Pfizer Inc.; Merck & Co. Inc.; AbbVie Inc.; Bayer AG; Bristol-Myers Squibb Company; AstraZeneca PLC; Novartis AG; Astellas Pharma Inc.; Ipsen Group; Exelixis Inc.; Ferring Pharmaceuticals; Dendreon Pharmaceuticals LLC; Hinova Pharmaceuticals Inc.; Janux Therapeutics Inc.; Zenith Epigenetics Ltd.; Tavanta Therapeutics Inc.; Cardiff Oncology Inc.; Oncternal Therapeutics Inc.; Clarity Pharmaceuticals Ltd.; Convergent Therapeutics Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Metastatic Prostate Cancer Market Characteristics

3. Metastatic Prostate Cancer Market Trends And Strategies

4. Metastatic Prostate Cancer Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Metastatic Prostate Cancer Growth Analysis And Strategic Analysis Framework

• 5.1. Global Metastatic Prostate Cancer PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Metastatic Prostate Cancer Market Growth Rate Analysis
• 5.4. Global Metastatic Prostate Cancer Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Metastatic Prostate Cancer Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Metastatic Prostate Cancer Total Addressable Market (TAM)

6. Metastatic Prostate Cancer Market Segmentation

• 6.1. Global Metastatic Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Chemotherapy
• Immunotherapy
• Hormonal Therapy
• Radiation Therapy
• Other Treatments
• 6.2. Global Metastatic Prostate Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Parenteral Route
• Intravenous
• Intrathecal
• Intraperitoneal
• Intra-Arterial
• Topical
• 6.3. Global Metastatic Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Other Distribution Channels
• 6.4. Global Metastatic Prostate Cancer Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Clinics
• Cancer Centers
• Research Laboratories
• Other End-Users
• 6.5. Global Metastatic Prostate Cancer Market, Sub-Segmentation Of Chemotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Docetaxel
• Cabazitaxel
• Mitoxantrone
• Combination Chemotherapy Regimens
• 6.6. Global Metastatic Prostate Cancer Market, Sub-Segmentation Of Immunotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Sipuleucel-T
• Immune Checkpoint Inhibitors
• Cancer Vaccines
• Cytokine Therapies
• 6.7. Global Metastatic Prostate Cancer Market, Sub-Segmentation Of Hormonal Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Luteinizing Hormone-Releasing Hormone (LHRH) Agonists
• LHRH Antagonists
• Anti-Androgens
• Androgen Synthesis Inhibitors
• Combined Androgen Blockade (CAB)
• 6.8. Global Metastatic Prostate Cancer Market, Sub-Segmentation Of Radiation Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• External Beam Radiation Therapy (EBRT)
• Stereotactic Body Radiotherapy (SBRT)
• Radiopharmaceutical Therapy
• Intensity-Modulated Radiation Therapy (IMRT)
• 6.9. Global Metastatic Prostate Cancer Market, Sub-Segmentation Of Other Treatments, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Targeted Therapy
• Bone-Targeted Therapy
• Clinical Trial Drugs
• Palliative Therapy

7. Metastatic Prostate Cancer Market Regional And Country Analysis

• 7.1. Global Metastatic Prostate Cancer Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Metastatic Prostate Cancer Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Metastatic Prostate Cancer Market

• 8.1. Asia-Pacific Metastatic Prostate Cancer Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Metastatic Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Metastatic Prostate Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Metastatic Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Metastatic Prostate Cancer Market

• 9.1. China Metastatic Prostate Cancer Market Overview
• 9.2. China Metastatic Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Metastatic Prostate Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Metastatic Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Metastatic Prostate Cancer Market

• 10.1. India Metastatic Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Metastatic Prostate Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Metastatic Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Metastatic Prostate Cancer Market

• 11.1. Japan Metastatic Prostate Cancer Market Overview
• 11.2. Japan Metastatic Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Metastatic Prostate Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Metastatic Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Metastatic Prostate Cancer Market

• 12.1. Australia Metastatic Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Metastatic Prostate Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Metastatic Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Metastatic Prostate Cancer Market

• 13.1. Indonesia Metastatic Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Metastatic Prostate Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Metastatic Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Metastatic Prostate Cancer Market

• 14.1. South Korea Metastatic Prostate Cancer Market Overview
• 14.2. South Korea Metastatic Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Metastatic Prostate Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Metastatic Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Metastatic Prostate Cancer Market

• 15.1. Western Europe Metastatic Prostate Cancer Market Overview
• 15.2. Western Europe Metastatic Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Metastatic Prostate Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Metastatic Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Metastatic Prostate Cancer Market

• 16.1. UK Metastatic Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Metastatic Prostate Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Metastatic Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Metastatic Prostate Cancer Market

• 17.1. Germany Metastatic Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Metastatic Prostate Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Metastatic Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Metastatic Prostate Cancer Market

• 18.1. France Metastatic Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Metastatic Prostate Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Metastatic Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Metastatic Prostate Cancer Market

• 19.1. Italy Metastatic Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Metastatic Prostate Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Metastatic Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Metastatic Prostate Cancer Market

• 20.1. Spain Metastatic Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Metastatic Prostate Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Metastatic Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Metastatic Prostate Cancer Market

• 21.1. Eastern Europe Metastatic Prostate Cancer Market Overview
• 21.2. Eastern Europe Metastatic Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Metastatic Prostate Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Metastatic Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Metastatic Prostate Cancer Market

• 22.1. Russia Metastatic Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Metastatic Prostate Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Metastatic Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Metastatic Prostate Cancer Market

• 23.1. North America Metastatic Prostate Cancer Market Overview
• 23.2. North America Metastatic Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Metastatic Prostate Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Metastatic Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Metastatic Prostate Cancer Market

• 24.1. USA Metastatic Prostate Cancer Market Overview
• 24.2. USA Metastatic Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Metastatic Prostate Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Metastatic Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Metastatic Prostate Cancer Market

• 25.1. Canada Metastatic Prostate Cancer Market Overview
• 25.2. Canada Metastatic Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Metastatic Prostate Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Metastatic Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Metastatic Prostate Cancer Market

• 26.1. South America Metastatic Prostate Cancer Market Overview
• 26.2. South America Metastatic Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Metastatic Prostate Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Metastatic Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Metastatic Prostate Cancer Market

• 27.1. Brazil Metastatic Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Metastatic Prostate Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Metastatic Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Metastatic Prostate Cancer Market

• 28.1. Middle East Metastatic Prostate Cancer Market Overview
• 28.2. Middle East Metastatic Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Metastatic Prostate Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Metastatic Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Metastatic Prostate Cancer Market

• 29.1. Africa Metastatic Prostate Cancer Market Overview
• 29.2. Africa Metastatic Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Metastatic Prostate Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Metastatic Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Metastatic Prostate Cancer Market Competitive Landscape And Company Profiles

• 30.1. Metastatic Prostate Cancer Market Competitive Landscape
• 30.2. Metastatic Prostate Cancer Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis

31. Metastatic Prostate Cancer Market Other Major And Innovative Companies

• 31.1. AstraZeneca PLC
• 31.2. Novartis AG
• 31.3. Astellas Pharma Inc.
• 31.4. Ipsen Group
• 31.5. Exelixis Inc.
• 31.6. Ferring Pharmaceuticals
• 31.7. Dendreon Pharmaceuticals LLC
• 31.8. Hinova Pharmaceuticals Inc.
• 31.9. Janux Therapeutics Inc.
• 31.10. Zenith Epigenetics Ltd.
• 31.11. Tavanta Therapeutics Inc.
• 31.12. Cardiff Oncology Inc.
• 31.13. Oncternal Therapeutics Inc.
• 31.14. Clarity Pharmaceuticals Ltd.
• 31.15. Convergent Therapeutics Inc.

32. Global Metastatic Prostate Cancer Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Metastatic Prostate Cancer Market

34. Recent Developments In The Metastatic Prostate Cancer Market

35. Metastatic Prostate Cancer Market High Potential Countries, Segments and Strategies

• 35.1 Metastatic Prostate Cancer Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Metastatic Prostate Cancer Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Metastatic Prostate Cancer Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer

관련자료